INS and metabolic dysfunction-associated steatotic liver disease: Consistent with the findings, Shao et al conducted an RCT study where 60 newly diagnosed patients with T2DM and NAFLD were randomly assigned into the exenatide group (exenatide and insulin glargine, n = 30) and the intensive insulin group (insulin aspart and insulin glargine, n = 30) for 12 weeks.